Sintilimab

Sintilimab
Monoclonal antibody
Type?
Clinical data
Other namesAnti-PD-1 monoclonal antibody IBI308[1]
Identifiers
CAS Number
UNII
KEGG

Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease,[2] and has been approved in China.[3]

It is a fully human IgG4 monoclonal antibody[4] that binds to programmed cell death protein 1.[5]

It was jointly developed by Innovent Biologics[6] and Eli Lilly.[7]

Medical uses

Sintilimab is medication that is indicated for the treatment of relapsed or refractory classical Hodgkin's lymphoma[8] after failure of at least second-line systemic chemotherapy.[5]

Side effects

Common side effects include fever, thyroid dysfunction, elevation of liver enzymes, and lung inflammation.[9]

Research

Currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors.[10] In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published.[8]

References

  1. ↑ "anti-PD-1 monoclonal antibody IBI308". NCI Drug Dictionary. National Cancer Institute. 2011-02-02.
  2. ↑ "Antibody Drug Conjugates Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026". Reuters. October 24, 2018.
  3. ↑ "NMPA Approves Tyvyt For Hodgkin's lymphoma Read". Asian Scientist Magazine. January 9, 2019.
  4. ↑ Ying K, Xu N, Jiang H, Liu Y, Zhou H, Wang S (2018). "OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer". Journal of Thoracic Oncology. 13 (12): S1047. doi:10.1016/j.jtho.2018.10.018. Retrieved Dec 1, 2018.
  5. 1 2 Hoy SM (February 2019). "Sintilimab: First Global Approval". Drugs. 79 (3): 341–346. doi:10.1007/s40265-019-1066-z. PMID 30742278. S2CID 59945274.
  6. ↑ "Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company". SEC.gov. December 20, 2018.
  7. ↑ "Sintilimab - Eli Lilly/Innovent Biologics". Adis Insight. Springer Nature Switzerland AG. 28 March 2019.
  8. 1 2 Ansell SM (January 2019). "Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma". The Lancet. Haematology. 6 (1): e2–e3. doi:10.1016/S2352-3026(18)30210-2. PMID 30612711. S2CID 58561198.
  9. ↑ A first-in-human phase 1a trial of sintilimab (IBI308). 2018 ASCO Annual Meeting. American Society of Clinical Oncology. 12 October 2019.
  10. ↑ Innovent Biologics, Inc. "Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection)". PR NewsWire. Retrieved Feb 22, 2019.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.